RxDoctor Payments Data

Janis Freeman

Family · Johnstown, NYNPI 1730493214

Payments from drug & device makers

$2,003in general payments, 2019–2025

Across 89 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$448
  • Novo Nordisk$319
  • AbbVie$314
  • GSK$153
  • Pfizer$149
  • Lundbeck LLC$135
  • plus $485 from 9 others

What the payments were for

  • Food & beverage$2,003100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,003 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$11,979
Medicare patients
43
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$52,385
JardianceEmpagliflozin45$51,562
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$24,760
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$24,081
TrulicityDulaglutide21$22,522
Breo ElliptaFluticasone/Vilanterol12$8,821
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,913
Albuterol Sulfate HfaAlbuterol Sulfate59$2,362
Pregabalin25$2,205
Rosuvastatin Calcium119$1,305
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,166
Levothyroxine Sodium81$1,147
Omeprazole79$926
Gabapentin51$684
Atorvastatin Calcium84$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$319$52,38548 claims
Boehringer IngelheimJardiance$25$51,56245 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$153$40,49457 claims
AstraZenecaBreztri Aerosphere$448$24,08133 claims
Lilly USA, LLCTrulicity$62$22,52221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Johnstown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →